Literature DB >> 12922968

European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteria.

G Valentini1, W Bencivelli, S Bombardieri, S D'Angelo, A Della Rossa, A J Silman, C M Black, L Czirjak, H Nielsen, P G Vlachoyiannopoulos.   

Abstract

OBJECTIVE: To further assess the construct validity of the three European Scleroderma Study Group (EScSG) preliminary activity indices for systemic sclerosis (SSc): for SSc as a whole, for diffuse SSc (dcSSc), and for limited SSc (lcSSc).
METHODS: 30/290 SSc clinical charts collected for the EScSG study used to develop activity criteria for SSc were selected and sent to four clinical experts in SSc. The experts ranked the charts from 1 to 30 (1=lowest activity, 30=highest activity). The relationships among the ranks given by each investigator and each of the three scores, and between any two of the ranks were investigated.
RESULTS: A consistently significant correlation (r(s)=0.530-0.712) was found between the ranks given by each of the four investigators and the index for the entire patient group. A similar level of agreement was detected between each couple of the four experts (r(s)=0.428-0.720). Moreover, the ranks given in patients with an index >3 were significantly higher than those given for patients with an index < or =3. This cut off point had previously been shown to best discriminate patients with active disease.
CONCLUSIONS: Of the originally developed activity indexes, the whole series index has been externally validated. The index comprises the first preliminary, but necessary, groundwork to improve the concept of disease activity in SSc, which is still ill defined. It can be used as a preliminary activity index in clinical investigational studies.

Entities:  

Mesh:

Year:  2003        PMID: 12922968      PMCID: PMC1754649          DOI: 10.1136/ard.62.9.901

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  45 in total

1.  What does the clinician need to improve patient care in systemic sclerosis?

Authors:  Madelon C Vonk; Frank H J van den Hoogen; Piet L C M van Riel; Gabriele Valentini
Journal:  Ann Rheum Dis       Date:  2007-09       Impact factor: 19.103

Review 2.  Biomarkers in the management of scleroderma: an update.

Authors:  Giuseppina Abignano; Maya Buch; Paul Emery; Francesco Del Galdo
Journal:  Curr Rheumatol Rep       Date:  2011-02       Impact factor: 4.592

3.  Human cytomegalovirus pp65 lower matrix protein: a humoral immunogen for systemic lupus erythematosus patients and autoantibody accelerator for NZB/W F1 mice.

Authors:  M Chang; M-R Pan; D-Y Chen; J-L Lan
Journal:  Clin Exp Immunol       Date:  2006-01       Impact factor: 4.330

4.  Clinical correlates of human leucocyte antigen (HLA)-G in systemic sclerosis.

Authors:  E Favoino; I E Favia; S Vettori; C Vicenti; M Prete; G Valentini; F Perosa
Journal:  Clin Exp Immunol       Date:  2015-05-10       Impact factor: 4.330

5.  Evaluation of differences in carotid intima-media thickness in patients affected by systemic rheumatic diseases.

Authors:  Marco Matteo Ciccone; Pietro Scicchitano; Annapaola Zito; Francesca Cortese; Cinzia Rotondo; Laura Coladonato; Michele Gesualdo; Antonella Notarnicola; Florenzo Iannone
Journal:  Intern Emerg Med       Date:  2015-06-03       Impact factor: 3.397

Review 6.  [Systemic sclerosis - diagnosis and classification].

Authors:  E Genth; T Krieg
Journal:  Z Rheumatol       Date:  2006-07       Impact factor: 1.372

7.  Autologous hematopoietic stem cell transplantation has better outcomes than conventional therapies in patients with rapidly progressive systemic sclerosis.

Authors:  N Del Papa; F Onida; E Zaccara; G Saporiti; W Maglione; E Tagliaferri; R Andracco; D Vincenti; T Montemurro; L Mircoli; C Vitali; A Cortelezzi
Journal:  Bone Marrow Transplant       Date:  2016-08-22       Impact factor: 5.483

8.  Age-associated alteration in Th17 cell response is related to endothelial cell senescence and atherosclerotic cerebral infarction.

Authors:  Qing Li; Shaowei Ding; Yuan Min Wang; Xiaoling Xu; Zuojun Shen; Rui Fu; Mengdie Liu; Chaojie Hu; Cuiping Zhang; Qi Cao; Yiping Wang
Journal:  Am J Transl Res       Date:  2017-11-15       Impact factor: 4.060

9.  What is the relationship between disease activity, severity and damage in a large Canadian systemic sclerosis cohort? Results from the Canadian Scleroderma Research Group (CSRG).

Authors:  Xiangning Fan; Janet Pope; Murray Baron
Journal:  Rheumatol Int       Date:  2009-09-24       Impact factor: 2.631

10.  Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patients.

Authors:  Katharina Hanke; Claudia S Brückner; Cornelia Dähnrich; Dörte Huscher; Lars Komorowski; Wolfgang Meyer; Anthonia Janssen; Marina Backhaus; Mike Becker; Angela Kill; Karl Egerer; Gerd R Burmester; Falk Hiepe; Wolfgang Schlumberger; Gabriela Riemekasten
Journal:  Arthritis Res Ther       Date:  2009-02-16       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.